Effects on Bone Resorption Markers of Continuing Pamidronate or Switching to Zoledronic Acid in Patients with High Risk Bone Metastases from Breast Cancer

Conclusion Our analysis failed to find any association between serum BSAP, BSP, CTx or NTx levels and subsequent SRE risk in this cohort of patients. This lack of correlation between serum biomarkers and clinical outcomes could be due to influences of prior bisphosphonate treatment or presence of extra-osseous metastases in a significant proportion of enrolled patients. As such, caution should be used in biomarker interpretation and use to direct decision making regarding SRE risk for high risk patients in this setting.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research